Nevirapine Mylan 400 mg depottabletti Finlândia - finlandês - Fimea (Suomen lääkevirasto)

nevirapine mylan 400 mg depottabletti

mylan ab - nevirapine - depottabletti - 400 mg - nevirapiini

Ritonavir Mylan União Europeia - finlandês - EMA (European Medicines Agency)

ritonavir mylan

mylan s.a.s - ritonaviiri - hiv-infektiot - antiviraalit systeemiseen käyttöön - ritonaviiri on merkitty yhdistelmänä muiden antiretroviraalisten aineiden kanssa hiv 1 -infektoituneiden potilaiden (aikuisten ja 2-vuotiaiden ja sitä vanhempien lasten).

Sunitinib Mylan 12.5 mg kapseli, kova Finlândia - finlandês - Fimea (Suomen lääkevirasto)

sunitinib mylan 12.5 mg kapseli, kova

mylan ab - sunitinib - kapseli, kova - 12.5 mg - sunitinibi

Sunitinib Mylan 25 mg kapseli, kova Finlândia - finlandês - Fimea (Suomen lääkevirasto)

sunitinib mylan 25 mg kapseli, kova

mylan ab - sunitinib - kapseli, kova - 25 mg - sunitinibi

Sunitinib Mylan 37.5 mg kapseli, kova Finlândia - finlandês - Fimea (Suomen lääkevirasto)

sunitinib mylan 37.5 mg kapseli, kova

mylan ab - sunitinib - kapseli, kova - 37.5 mg - sunitinibi

Sunitinib Mylan 50 mg kapseli, kova Finlândia - finlandês - Fimea (Suomen lääkevirasto)

sunitinib mylan 50 mg kapseli, kova

mylan ab - sunitinib - kapseli, kova - 50 mg - sunitinibi

Fingolimod Mylan União Europeia - finlandês - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochloride - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1)orpatients kanssa vaikea ja nopeasti etenevä relapsoiva-remittoiva multippeliskleroosi on määritelty 2 tai enemmän invaliditeettiin sairauden pahenemisvaiheita on yksi vuosi, ja 1 tai enemmän gadolinium parantaa vaurioita aivojen mri tai merkittävä kasvu t2-leesio kuormitus verrattuna aiempaan tuoreeseen magneettikuvaukseen.

Fingolimod Mylan União Europeia - finlandês - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochloride - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Ticagrelor Mylan 90 mg tabletti, kalvopäällysteinen Finlândia - finlandês - Fimea (Suomen lääkevirasto)

ticagrelor mylan 90 mg tabletti, kalvopäällysteinen

mylan ab - ticagrelorum - tabletti, kalvopäällysteinen - 90 mg - tikagrelori

Ticagrelor Mylan 60 mg tabletti, kalvopäällysteinen Finlândia - finlandês - Fimea (Suomen lääkevirasto)

ticagrelor mylan 60 mg tabletti, kalvopäällysteinen

mylan ab - ticagrelorum - tabletti, kalvopäällysteinen - 60 mg - tikagrelori